Notably, in chronic myeloid leukemia (CML), PTPRG is significantly downregulated in leukemic cells at diagnosis, and PTPRG hypermethylation has been identified as an independent mechanism of resistance to tyrosine kinase inhibitor therapy (12). The gene discussed is PTPRG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.